Brief: Zevra Therapeutics Transitions To Orsini As The Specialty Pharmacy Provider For Olpruva, A Treatment For Certain Urea Cycle Disorders
18/06/2024 13:02
June 18 (Reuters) - Zevra Therapeutics Inc ZVRA.O :
* ZEVRA THERAPEUTICS TRANSITIONS TO ORSINI AS THE SPECIALTY
PHARMACY PROVIDER FOR OLPRUVA® (SODIUM PHENYLBUTYRATE), A
TREATMENT FOR CERTAIN UREA CYCLE DISORDERS
Source text for Eikon: ID:nPn5lMnbma
Further company coverage: ZVRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor